ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Valeant To Buy Branded Generics Assets From Gerot Lannach

DOW JONES NEWSWIRES Valeant Pharmaceuticals International Inc. (VRX) said Tuesday it's acquiring from Austria's Gerot Lannach certain branded generics assets that generate the bulk of their sales in Russia. Mississauga, Ont.-based Valeant said the assets generated net revenue of about $55 million last year. Gerot Lannach's largest product is acetylsalicylic acid, a low-dose aspirin. Valeant said it will pay less than three times sales, and may make up to an additional $20 million in milestone payments, based upon future performance objectives. As part of the transaction, Valeant and Gerot Lannach will enter into a strategic partnership that includes an exclusive 10-year supply agreement for the acquired products and the opportunity for Valeant to introduce additional Gerot Lannach products into Valeant territories such as its emerging markets in Southeast Asia and Latin America. Valeant expects the transaction to boost results starting immediately. -By Carolyn King, Dow Jones Newswires; 416-306-2100; carolyn.m.king@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
04/30/201515:43:06Quarterly Report (10-q)
04/30/201512:32:00Pharming Reports on Annual General Meeting of Shareholders
04/30/201511:44:41Deutsche Bank Raises Valeant Pharmaceuticals Intl Price Target...
04/30/201510:34:48Barclays Boosts Valeant Pharmaceuticals Intl Price Target to...
04/30/201504:52:49Valeant Pharmaceuticals Intl PT Raised to $271.00 (VRX)
04/30/201503:37:17RBC Capital Raises Valeant Pharmaceuticals Intl Price Target...
04/30/201503:22:34Valeant Pharmaceuticals Intl Given New $250.00 Price Target at...
04/30/201501:00:00Pharming Reports on Financial Results for Q1 2015
04/29/201515:22:11Morgan Stanley Analysts Give Valeant Pharmaceuticals Intl a $223.00...
04/29/201507:40:10Valeant Boosts 2015 Outlook
04/29/201507:10:09Valeant Boosts 2015 Outlook as Results Top Views
04/29/201506:11:49Current Report Filing (8-k)
04/29/201506:10:40Current Report Filing (8-k)
04/29/201506:00:00Valeant Announces CFO Succession Plan And Additional Executive...
04/29/201506:00:00Valeant Pharmaceuticals Reports First Quarter 2015 Financial...
04/29/201506:00:00Valeant Announces CFO Succession Plan And Additional Executive...
04/29/201506:00:00Valeant Pharmaceuticals Reports First Quarter 2015 Financial...
04/28/201516:42:03Statement of Changes in Beneficial Ownership (4)
04/28/201516:27:20Statement of Changes in Beneficial Ownership (4)
04/28/201516:10:33Statement of Changes in Beneficial Ownership (4)

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad